BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 24319222)

  • 21. The road to treating smoldering multiple myeloma.
    Korde N; Mailankody S; Landgren O
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S59-64. PubMed ID: 25486957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
    Hermouet S; Bigot-Corbel E; Harb J
    Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host-related immunodeficiency in the development of multiple myeloma.
    Dosani T; Mailankody S; Korde N; Manasanch E; Bhutani M; Tageja N; Roschewski M; Kwok M; Kazandjian D; Costello R; Burton D; Zhang Y; Liewehr D; Steinberg SM; Maric I; Landgren O
    Leuk Lymphoma; 2018 May; 59(5):1127-1132. PubMed ID: 28792255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
    Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
    Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent Advances in the Management of Smoldering Multiple Myeloma.
    Madhira BR; Konala VM; Adapa S; Naramala S; Ravella PM; Parikh K; Gentile TC
    World J Oncol; 2020 Apr; 11(2):45-54. PubMed ID: 32284772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
    BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.
    Gkotzamanidou M; Christoulas D; Souliotis VL; Papatheodorou A; Dimopoulos MA; Terpos E
    Med Sci Monit; 2013 Dec; 19():1188-94. PubMed ID: 24355943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.
    Waxman AJ; Kuehl M; Balakumaran A; Weiss B; Landgren O
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):248-57. PubMed ID: 20709660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
    Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
    Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular imaging in myeloma precursor disease.
    Mena E; Choyke P; Tan E; Landgren O; Kurdziel K
    Semin Hematol; 2011 Jan; 48(1):22-31. PubMed ID: 21232655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymptomatic monoclonal gammopathies.
    Bories C; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S78-86. PubMed ID: 25486961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.
    Landgren O; Kyle RA; Rajkumar SV
    Clin Cancer Res; 2011 Mar; 17(6):1243-52. PubMed ID: 21411440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L
    Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoldering multiple myeloma.
    Rajkumar SV; Landgren O; Mateos MV
    Blood; 2015 May; 125(20):3069-75. PubMed ID: 25838344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
    Rajkumar SV
    Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.